` Comparison: 4883 vs ABBV - Alpha Spread

4883
vs
ABBV

Over the past 12 months, Modalis Therapeutics Corp has underperformed ABBV, delivering a return of -32% compared to the ABBV's +10% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
4883
ABBV
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

Modalis Therapeutics Corp Intrinsic Value
HIDDEN
Show
ABBV Intrinsic Value
HIDDEN
Show
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
Modalis Therapeutics Corp
TSE:4883
59 JPY
Abbvie Inc
NYSE:ABBV
229.92 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
4883, ABBV

4883
ABBV
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Modalis Therapeutics Corp
Revenue
Abbvie Inc
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
4883, ABBV

4883
ABBV
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Modalis Therapeutics Corp
TSE:4883
Abbvie Inc
NYSE:ABBV
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

Modalis Therapeutics Corp
0%
ABBV
71.2%

Operating Margin

Modalis Therapeutics Corp
0%
ABBV
33.1%

Net Margin

Modalis Therapeutics Corp
0%
ABBV
3.9%

FCF Margin

Modalis Therapeutics Corp
0%
ABBV
33%

ROE

Modalis Therapeutics Corp
-67.9%
ABBV
138.5%

ROA

Modalis Therapeutics Corp
-64.7%
ABBV
1.7%

ROIC

Modalis Therapeutics Corp
-1 650.8%
ABBV
28.4%

ROCE

Modalis Therapeutics Corp
-69.1%
ABBV
20.2%

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
4883, ABBV

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
4883, ABBV

Performance Gap Between 4883 and ABBV
HIDDEN
Show

Performance By Year
4883, ABBV

Loading
4883
ABBV
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare 4883 to other stocks
PNEXF
Pharnext SCA
More expensive
vs Modalis Therapeutics Corp
ATXS
Astria Therapeutics Inc
More expensive
vs Modalis Therapeutics Corp
AMGN
Amgen Inc
More expensive
vs Modalis Therapeutics Corp
GILD
Gilead Sciences Inc
More expensive
vs Modalis Therapeutics Corp
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett